Journal

Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614

Informations de publication

Date de publication:
15 06 2023
Historique:
medline: 19 6 2023
pubmed: 20 4 2023
entrez: 20 04 2023
Statut: ppublish

Résumé

In view of the current increase and spread of antimicrobial resistance (AMR), there is an urgent need to find new strategies to combat it. This study had two aims. First, we synthesized highly monodispersed silver nanoparticles (AgNPs) of approximately 17 nm, and we functionalized them with mercaptopoly(ethylene glycol) carboxylic acid (mPEG-COOH) and amikacin (AK). Second, we evaluated the antibacterial activity of this treatment (AgNPs_mPEG_AK) alone and in combination with hyperthermia against planktonic and biofilm-growing strains. AgNPs, AgNPs_mPEG, and AgNPs_mPEG_AK were characterized using a suite of spectroscopy and microscopy methods. Susceptibility to these treatments and AK was determined after 24 h and over time against 12 clinical multidrug-resistant (MDR)/extensively drug-resistant (XDR) isolates of Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. The efficacy of the treatments alone and in combination with hyperthermia (1, 2, and 3 pulses at 41°C to 42°C for 15 min) was tested against the same planktonic strains using quantitative culture and against one P. aeruginosa strain growing on silicone disks using confocal laser scanning microscopy. The susceptibility studies showed that AgNPs_mPEG_AK was 10-fold more effective than AK alone, and bactericidal efficacy after 4, 8, 24, or 48 h was observed against 100% of the tested strains. The combination of AgNPs_mPEG_AK and hyperthermia eradicated 75% of the planktonic strains and exhibited significant reductions in biofilm formation by P. aeruginosa in comparison with the other treatments tested, except for AgNPs_mPEG_AK without hyperthermia. In conclusion, the combination of AgNPs_mPEG_AK and hyperthermia may be a promising therapy against MDR/XDR and biofilm-producing strains.

Identifiants

pubmed: 37078875
doi: 10.1128/spectrum.00280-23
pmc: PMC10269648
doi:

Substances chimiques

Amikacin 84319SGC3C
monomethoxypolyethylene glycol 9004-74-4
Silver 3M4G523W1G
Anti-Bacterial Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0028023

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

Biomed Res Int. 2016;2016:2475067
pubmed: 27274985
Langmuir. 2016 Sep 27;32(38):9807-15
pubmed: 27578534
Front Microbiol. 2016 Nov 16;7:1831
pubmed: 27899918
Expert Rev Anti Infect Ther. 2012 Apr;10(4):459-73
pubmed: 22512755
Nat Med. 2004 Dec;10(12 Suppl):S122-9
pubmed: 15577930
Braz J Microbiol. 2021 Mar;52(1):267-278
pubmed: 33231865
Bioconjug Chem. 2020 Jan 15;31(1):139-148
pubmed: 31860279
Nat Rev Drug Discov. 2003 Feb;2(2):114-22
pubmed: 12563302
Clin Microbiol Rev. 2002 Apr;15(2):167-93
pubmed: 11932229
Nanomaterials (Basel). 2016 Apr 15;6(4):
pubmed: 28335201
Sci Rep. 2018 Jan 9;8(1):201
pubmed: 29317760
Part Fibre Toxicol. 2011 Dec 30;8:36
pubmed: 22208550
Mol Pharm. 2009 Sep-Oct;6(5):1388-401
pubmed: 19473014
RSC Adv. 2019 Jan 9;9(2):1095-1105
pubmed: 35517620
Adv Drug Deliv Rev. 2013 Nov;65(13-14):1803-15
pubmed: 23892192
Lancet Infect Dis. 2013 Dec;13(12):1057-98
pubmed: 24252483
Int J Mol Sci. 2019 Jan 21;20(2):
pubmed: 30669621
Lancet. 2022 Feb 12;399(10325):629-655
pubmed: 35065702
Antibiotics (Basel). 2022 Sep 08;11(9):
pubmed: 36139997
Molecules. 2015 May 18;20(5):8856-74
pubmed: 25993417
Biofouling. 2015;31(8):665-75
pubmed: 26371591
Nat Rev Microbiol. 2004 Feb;2(2):95-108
pubmed: 15040259
Nanomedicine (Lond). 2011 Jun;6(4):715-28
pubmed: 21718180
Int J Mol Sci. 2019 Feb 17;20(4):
pubmed: 30781560
Ther Deliv. 2011 Aug;2(8):1001-14
pubmed: 22506095
J Nanopart Res. 2017;19(8):273
pubmed: 28824288
Emerg Infect Dis. 2002 Sep;8(9):881-90
pubmed: 12194761
Front Microbiol. 2019 Apr 01;10:539
pubmed: 30988669
Nanomaterials (Basel). 2017 Jan 06;7(1):
pubmed: 28336841
Am J Infect Control. 2023 Aug;51(8):871-878
pubmed: 36581226
Lancet. 2016 Jan 9;387(10014):168-75
pubmed: 26603918
Evid Based Complement Alternat Med. 2015;2015:246012
pubmed: 25861355
Appl Environ Microbiol. 2012 Apr;78(8):2768-74
pubmed: 22286985
3 Biotech. 2021 Apr;11(4):169
pubmed: 33816046
Sci Rep. 2017 Jul 12;7(1):5259
pubmed: 28701753
Appl Environ Microbiol. 2016 Feb 12;82(7):2219-26
pubmed: 26873320
J Proteome Res. 2020 Aug 7;19(8):3109-3122
pubmed: 32567865
Int J Nanomedicine. 2019 Jan 18;14:667-687
pubmed: 30705586
N Engl J Med. 2010 Dec 16;363(25):2434-43
pubmed: 21158659
P T. 2015 Apr;40(4):277-83
pubmed: 25859123
Nat Protoc. 2008;3(12):1909-24
pubmed: 19180075
Microbiol Spectr. 2023 Feb 14;11(1):e0280722
pubmed: 36472442
Front Microbiol. 2018 Jul 02;9:1441
pubmed: 30013539
Vet J. 2016 Mar;209:174-9
pubmed: 26832810
Artif Cells Nanomed Biotechnol. 2018;46(sup3):S886-S899
pubmed: 30422688
Int J Hyperthermia. 2016;32(1):76-88
pubmed: 26757879

Auteurs

Marta Palau (M)

Antibiotic Resistance Laboratory, Vall d'Hebron Research Institute (VHIR), Infectious Diseases Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Spanish Network for Research in Infectious Diseases (REIPI RD19/0016), Instituto de Salud Carlos III, Madrid, Spain.
CIBERINFEC, ISCIII-CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.

Estela Muñoz (E)

Antibiotic Resistance Laboratory, Vall d'Hebron Research Institute (VHIR), Infectious Diseases Department, Vall d'Hebron University Hospital, Barcelona, Spain.

Muriel F Gusta (MF)

Institut Català de Nanociència i Nanotecnologia (ICN2), CSIC, The Barcelona Institute of Science and Technology (BIST), Campus UAB, Bellaterra, Barcelona, Spain.
Vall d'Hebron University Hospital, Barcelona, Spain.
CIBER en Bioingeniería, Biomateriales y Nanomedicina, CIBER-BBN, Madrid, Spain.

Nieves Larrosa (N)

Spanish Network for Research in Infectious Diseases (REIPI RD19/0016), Instituto de Salud Carlos III, Madrid, Spain.
CIBERINFEC, ISCIII-CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.
Microbiology Department, Vall d'Hebron University Hospital, Barcelona, Spain.

Xavier Gomis (X)

Antibiotic Resistance Laboratory, Vall d'Hebron Research Institute (VHIR), Infectious Diseases Department, Vall d'Hebron University Hospital, Barcelona, Spain.
CIBERINFEC, ISCIII-CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.

Joan Gilabert (J)

Tractivus SL, Barcelona, Spain.

Benito Almirante (B)

Antibiotic Resistance Laboratory, Vall d'Hebron Research Institute (VHIR), Infectious Diseases Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Spanish Network for Research in Infectious Diseases (REIPI RD19/0016), Instituto de Salud Carlos III, Madrid, Spain.
CIBERINFEC, ISCIII-CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.

Victor Puntes (V)

Institut Català de Nanociència i Nanotecnologia (ICN2), CSIC, The Barcelona Institute of Science and Technology (BIST), Campus UAB, Bellaterra, Barcelona, Spain.
Vall d'Hebron University Hospital, Barcelona, Spain.
CIBER en Bioingeniería, Biomateriales y Nanomedicina, CIBER-BBN, Madrid, Spain.
Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.

Robert Texidó (R)

Grup d'Enginyeria de Materials (GEMAT), Universitat Ramón Llull, Barcelona, Spain.

Joan Gavaldà (J)

Antibiotic Resistance Laboratory, Vall d'Hebron Research Institute (VHIR), Infectious Diseases Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Spanish Network for Research in Infectious Diseases (REIPI RD19/0016), Instituto de Salud Carlos III, Madrid, Spain.
CIBERINFEC, ISCIII-CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.

Articles similaires

Vancomycin-associated DRESS demonstrates delay in AST abnormalities.

Ahmed Hussein, Kateri L Schoettinger, Jourdan Hydol-Smith et al.
1.00
Humans Drug Hypersensitivity Syndrome Vancomycin Female Male
Humans Arthroplasty, Replacement, Elbow Prosthesis-Related Infections Debridement Anti-Bacterial Agents
Vancomycin Polyesters Anti-Bacterial Agents Models, Theoretical Drug Liberation
Biofilms Candida albicans Quorum Sensing Candida glabrata Menthol

Classifications MeSH